{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:01:28Z","timestamp":1771545688654,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"DOI":"10.1186\/s41824-026-00289-5","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:03:32Z","timestamp":1771542212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of Choline-PET\/CT in patients with recurrent prostate cancer and a negative PSMA-PET\/CT"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4597-2312","authenticated-orcid":false,"given":"Nasir","family":"G\u00f6zl\u00fcg\u00f6l","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram A.","family":"Bosbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Sari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arion","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"1","key":"289_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1053\/j.sult.2024.11.005","volume":"46","author":"E Abramczyk","year":"2025","unstructured":"Abramczyk E, Nisar MU, Nguyen JK et al (2025 Feb) The role of prostate-specific membrane antigen-radioligand and magnetic resonance imaging in patients with prostate cancer biochemical recurrence. Semin Ultrasound CT MR 46(1):71\u201382. https:\/\/doi.org\/10.1053\/j.sult.2024.11.005","journal-title":"Semin Ultrasound CT MR"},{"issue":"2","key":"289_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00259-023-06438-3","volume":"51","author":"S Adebahr","year":"2024","unstructured":"Adebahr S, Althaus A, Scharl S et al (2024 Jan) The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imag 51(2):558\u2013567. https:\/\/doi.org\/10.1007\/s00259-023-06438-3","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"289_CR3","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","volume":"48","author":"A Afshar-Oromieh","year":"2021","unstructured":"Afshar-Oromieh A, da Cunha ML, Wagner J et al (2021 Aug) Performance of [68Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imag 48(9):2925\u20132934. https:\/\/doi.org\/10.1007\/s00259-021-05189-3","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"289_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Haberkorn U, Schlemmer HP et al (2014 May) Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imag 41(5):887\u2013897. https:\/\/doi.org\/10.1007\/s00259-013-2660-z","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"289_CR5","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/s00259-017-3718-0","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Wolf M, Haberkorn U et al (2017) Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET\/MRI. Eur J Nucl Med Mol Imag 44(10):1636\u20131646. https:\/\/doi.org\/10.1007\/s00259-017-3718-0","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"289_CR6","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.2967\/jnumed.120.257741","volume":"62","author":"I Alberts","year":"2021","unstructured":"Alberts I, Niklas-H\u00fcnermund, Sachpekidis C et al (2021) Combination of forced diuresis with additional late imaging in [6 8 Ga]Ga-PSMA-11 PET\/CT: effects on lesion visibility and radiotracer uptake. J Nucl Med 62(9):1252\u20131257. https:\/\/doi.org\/10.2967\/jnumed.120.257741","journal-title":"J Nucl Med"},{"issue":"1","key":"289_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41824-018-0027-1","volume":"2","author":"R Alonso","year":"2018","unstructured":"Alonso R, Dos Santos G, Hobeika C et al (2018) Prospective comparison of 6 8 Ga-PSMA-PET\/CT and 1 1 C-Choline-PET\/CT in patients with prostate cancer and biochemical relapse. Eur J Hybrid Imag 2(1):17. https:\/\/doi.org\/10.1186\/s41824-018-0027-1","journal-title":"Eur J Hybrid Imag"},{"issue":"2","key":"289_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","volume":"26","author":"MK Bakht","year":"2018","unstructured":"Bakht MK, Derecichei I, Li Y et al (2018) Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer 26(2):131\u2013146. https:\/\/doi.org\/10.1530\/ERC-18-0226. Published 2018 Nov 23","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"289_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00259-018-4249-z","volume":"46","author":"U Bashir","year":"2019","unstructured":"Bashir U, Tree A, Mayer E et al (2019 Apr) Impact of Ga-68-PSMA PET\/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imag 46(4):901\u2013907. https:\/\/doi.org\/10.1007\/s00259-018-4249-z","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"289_CR10","doi-asserted-by":"publisher","unstructured":"Beheshti M, Shahbazi-Akbari M, Hacker M et al (2025 68) Ga]Ga-PSMA-11 PET\/CT and [18F]F-Fluorocholine-PET\/CT in assessment and clinical decision making of recurrent prostate cancer: a prospective crossover trial. Mol Imag Biol. https:\/\/doi.org\/10.1007\/s11307-025-02020-5","DOI":"10.1007\/s11307-025-02020-5"},{"issue":"1","key":"289_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.21873\/invivo.11214","volume":"32","author":"D Buergy","year":"2018","unstructured":"Buergy D, Sertdemir M, Weidner A et al (2018 Jan-Feb) Detection of local recurrence with 3-tesla MRI after radical prostatectomy: a useful method for radiation treatment planning? Vivo 32(1):125\u2013131. https:\/\/doi.org\/10.21873\/invivo.11214","journal-title":"Vivo"},{"issue":"11","key":"289_CR12","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J, Kishan AU, Cao M et al (2018 Nov) Potential Impact of 68Ga-PSMA-11 PET\/CT on the Planning of definitive Radiation therapy for prostate cancer. J Nucl Med 59(11):1714\u20131721. https:\/\/doi.org\/10.2967\/jnumed.118.209387","journal-title":"J Nucl Med"},{"issue":"6","key":"289_CR13","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00259-020-05086-1","volume":"48","author":"Y Chevalme","year":"2021","unstructured":"Chevalme Y, Gauth\u00e9 M, Barbier R et al (2021) Evaluation of 6 8 Ga-PSMA-11 PET\/CT in patients with negative or equivocal 1 8 F-choline-PET\/CT for biochemical recurrence of prostate cancer: a French multicenter retrospective study. Eur J Nucl Med Mol Imag 48(6):1813\u20131821. https:\/\/doi.org\/10.1007\/s00259-020-05086-1","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"29","key":"289_CR14","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P et al (2022 Oct 10) Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol 40(29):3377\u20133382. https:\/\/doi.org\/10.1200\/JCO.22.00644","journal-title":"J Clin Oncol"},{"issue":"5","key":"289_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M et al (2015 May) Evaluation of Hybrid 6 8 Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56(5):668\u2013674. https:\/\/doi.org\/10.2967\/jnumed.115.154153","journal-title":"J Nucl Med"},{"issue":"4","key":"289_CR16","first-page":"359","volume":"59","author":"L Evangelista","year":"2015","unstructured":"Evangelista L, Zattoni F, Rossi E et al (2015 Dec) Early detection of prostate cancer relapse by biochemistry and diagnostic imaging. Q J Nucl Med Mol Imag 59(4):359\u2013373. Epub 2015 Jul 24. PMID: 26213139","journal-title":"Q J Nucl Med Mol Imag"},{"issue":"14","key":"289_CR17","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.7150\/thno.445","volume":"10","author":"DA Ferraro","year":"2020","unstructured":"Ferraro DA, R\u00fcschoff JH, Muehlematter UJ et al (2020 May 15) Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET. Theranostics 10(14):6082\u20136094. https:\/\/doi.org\/10.7150\/thno.445","journal-title":"Theranostics"},{"issue":"13","key":"289_CR18","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Gr\u00fcnig","year":"2021","unstructured":"Gr\u00fcnig H, Maurer A, Thali Y et al (2021) Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imag 48(13):4483\u20134494. https:\/\/doi.org\/10.1007\/s00259-021-05424-x","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"289_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40644-024-00752-1","volume":"24","author":"S Harsini","year":"2024","unstructured":"Harsini S, Martineau P, Plaha S et al (2024 Aug 30) Prognostic significance of a negative PSMA PET\/CT in biochemical recurrence of prostate cancer. Cancer Imag 24(1):117. https:\/\/doi.org\/10.1186\/s40644-024-00752-1","journal-title":"Cancer Imag"},{"issue":"17","key":"289_CR20","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.3390\/cancers13174270","volume":"13","author":"PE Hartrampf","year":"2021","unstructured":"Hartrampf PE, Lapa C, Serfling SE et al (2021) Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA Radioligand therapy and their possible influence on patient outcome. Cancers (Basel) 13(17):4270. https:\/\/doi.org\/10.3390\/cancers13174270. Published 2021 Aug 25","journal-title":"Cancers (Basel)"},{"key":"289_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00259-019-04548-5","volume":"47","author":"F Haupt","year":"2020","unstructured":"Haupt F, Dijkstra L, Alberts I et al (2020) 68Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. Eur J Nucl Med Mol Imag 47:624\u2013631. https:\/\/doi.org\/10.1007\/s00259-019-04548-5","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"289_CR22","doi-asserted-by":"publisher","unstructured":"Heu\u00dfer T, Mann P, Rank CM et al (2017) Investigation of the halo-artifact in 68Ga-PSMA-11-PET\/MRI. PLoS One 12(8):e0183329. https:\/\/doi.org\/10.1371\/journal.pone.0183329. Published 2017 Aug 17","DOI":"10.1371\/journal.pone.0183329"},{"issue":"3","key":"289_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.prnil.2022.05.001","volume":"10","author":"M Kim","year":"2022","unstructured":"Kim M, Hwang SI, Ahn H et al (2022 Sep) Diagnostic yield of multiparametric MRI for local recurrence at biochemical recurrence after radical prostatectomy. Prostate Int 10(3):135\u2013141. https:\/\/doi.org\/10.1016\/j.prnil.2022.05.001","journal-title":"Prostate Int"},{"issue":"6","key":"289_CR24","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF et al (2023 Jun) Updates to advanced prostate cancer: AUA\/SUO Guideline (2023). J Urol 209(6):1082\u20131090. https:\/\/doi.org\/10.1097\/JU.0000000000003452","journal-title":"J Urol"},{"issue":"9","key":"289_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4103\/1947-2714.100994","volume":"4","author":"A Massaro","year":"2012","unstructured":"Massaro A, Ferretti A, Secchiero C, a E (2012 Sep) Optimising (18)F-Choline PET\/CT acquisition protocol in prostate cancer patients. N Am J Med Sci 4(9):416\u2013420. https:\/\/doi.org\/10.4103\/1947-2714.100994","journal-title":"N Am J Med Sci"},{"issue":"6","key":"289_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","volume":"26","author":"P Ost","year":"2025","unstructured":"Ost P, Siva S, Brabrand S et al (2025 Jun) Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol 26(6):695\u2013706. https:\/\/doi.org\/10.1016\/S1470-2045(25)00197-4","journal-title":"Lancet Oncol"},{"key":"289_CR27","doi-asserted-by":"publisher","first-page":"109678","DOI":"10.1016\/j.radonc.2023.109678","volume":"184","author":"S Scharl","year":"2023","unstructured":"Scharl S, Zamboglou C, Strouthos I et al (2023 Jul) Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study. Radiother Oncol 184:109678. https:\/\/doi.org\/10.1016\/j.radonc.2023.109678","journal-title":"Radiother Oncol"},{"issue":"7","key":"289_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2967\/jnumed.118.220855","volume":"60","author":"NS Schmidt-Hegemann","year":"2019","unstructured":"Schmidt-Hegemann NS, Eze C, Li M et al (2019 Jul) Impact of 68Ga-PSMA PET\/CT on the radiotherapeutic approach to prostate cancer in Comparison to CT: a retrospective analysis. J Nucl Med 60(7):963\u2013970. https:\/\/doi.org\/10.2967\/jnumed.118.220855","journal-title":"J Nucl Med"},{"issue":"3","key":"289_CR29","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s00259-019-04508-0","volume":"47","author":"J Schwenck","year":"2020","unstructured":"Schwenck J, Rempp H, Reischl G et al (2020) Comparison of 6 8 Ga-PSMA-HBED-CC and 1 8 F-fluorocholine-PET\/CT in patients with early biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imag 47(3):710\u2013717. https:\/\/doi.org\/10.1007\/s00259-019-04508-0","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"8","key":"289_CR30","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00259-023-06185-5","volume":"50","author":"N Solomonidou","year":"2023","unstructured":"Solomonidou N, Germanou D, Strouthos I et al (2023 Jul) PSMA-PET\/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng\/ml. Eur J Nucl Med Mol Imag 50(8):2529\u20132536. https:\/\/doi.org\/10.1007\/s00259-023-06185-5","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"17","key":"289_CR31","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.19.02757","volume":"38","author":"EJ Trabulsi","year":"2020","unstructured":"Trabulsi EJ, Rumble RB, Jadvar H et al (2020 Jun 10) Optimum imaging strategies for advanced prostate cancer: ASCO Guideline. J Clin Oncol 38(17):1963\u20131996. https:\/\/doi.org\/10.1200\/JCO.19.02757","journal-title":"J Clin Oncol"},{"issue":"2","key":"289_CR32","first-page":"127","volume":"9","author":"G Treglia","year":"2019","unstructured":"Treglia G, Pereira Mestre R, Ferrari M, Bosetti DG et al (2019 Apr 15) Radiolabelled choline versus PSMA-PET\/CT in prostate cancer restaging: a meta-analysis. Am J Nucl Med Mol Imag 9(2):127\u2013139. PMID: 31139496; PMCID: PMC6526363","journal-title":"Am J Nucl Med Mol Imag"},{"issue":"6","key":"289_CR33","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s11912-025-01682-2","volume":"27","author":"L Wang","year":"2025","unstructured":"Wang L, Wang L, Wang X, Wu D (2025 Jun) The evolving role of PSMA-PET\/CT in prostate cancer management: an umbrella review of diagnostic restaging, therapeutic redirection, and survival Impact. Curr Oncol Rep 27(6):774\u2013787. https:\/\/doi.org\/10.1007\/s11912-025-01682-2","journal-title":"Curr Oncol Rep"},{"key":"289_CR34","doi-asserted-by":"publisher","first-page":"684629","DOI":"10.3389\/fonc.2021.684629","volume":"11","author":"R Wang","year":"2021","unstructured":"Wang R, Shen G, Huang M et al (2021) Comparison of 6 8 Ga-PSMA and 1 8 F-Choline-PET\/CT in the diagnosis of biochemical recurrence of prostate cancer: a meta-analysis. Front Oncol 11:684629. https:\/\/doi.org\/10.3389\/fonc.2021.684629","journal-title":"Front Oncol"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-026-00289-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:03:34Z","timestamp":1771542214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41824-026-00289-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["289"],"URL":"https:\/\/doi.org\/10.1186\/s41824-026-00289-5","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Cantonal Ethics Committee of Bern (Req-2024-00783). Written informed consent for data evaluation was obtained from all participants. All procedures were carried out in accordance with the Declaration of Helsinki and applicable national regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ali Afshar-Oromieh is a member of the Editorial Board of\n                      European Journal of Nuclear Medicine and Molecular Imaging\n                      . Hasan Sari has part time employment with Siemens Healthineers. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}